You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 13, 2024

CLINICAL TRIALS PROFILE FOR INSULIN DETEMIR RECOMBINANT


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Insulin Detemir Recombinant

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00095082 ↗ Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes Completed Novo Nordisk A/S Phase 3 2004-09-01 This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood glucose in basal/bolus therapy in patients with type I diabetes.
NCT00097084 ↗ Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes Completed Novo Nordisk A/S Phase 3 2004-09-01 This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood glucose in basal/bolus therapy in patients with type 2 diabetes.
NCT00104182 ↗ Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes Completed Novo Nordisk A/S Phase 3 2005-02-01 This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the use of Insulin Detemir once a day (morning or evening) to NPH Insulin once a day (evening) when added to treatment with oral antidiabetic drugs in patients with Type 2 diabetes.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Insulin Detemir Recombinant

Condition Name

Condition Name for Insulin Detemir Recombinant
Intervention Trials
Diabetes 122
Diabetes Mellitus, Type 2 87
Diabetes Mellitus, Type 1 58
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Insulin Detemir Recombinant
Intervention Trials
Diabetes Mellitus 163
Diabetes Mellitus, Type 2 109
Diabetes Mellitus, Type 1 71
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Insulin Detemir Recombinant

Trials by Country

Trials by Country for Insulin Detemir Recombinant
Location Trials
United States 561
Canada 50
United Kingdom 38
France 31
Germany 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Insulin Detemir Recombinant
Location Trials
Texas 32
California 30
Georgia 24
Florida 23
New York 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Insulin Detemir Recombinant

Clinical Trial Phase

Clinical Trial Phase for Insulin Detemir Recombinant
Clinical Trial Phase Trials
Phase 4 51
Phase 3 50
Phase 2 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Insulin Detemir Recombinant
Clinical Trial Phase Trials
Completed 164
Terminated 12
Unknown status 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Insulin Detemir Recombinant

Sponsor Name

Sponsor Name for Insulin Detemir Recombinant
Sponsor Trials
Novo Nordisk A/S 141
Sanofi 5
Eli Lilly and Company 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Insulin Detemir Recombinant
Sponsor Trials
Industry 167
Other 91
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.